Marquette Asset Management LLC Decreases Stock Holdings in Sera Prognostics, Inc. (NASDAQ:SERA)

Marquette Asset Management LLC reduced its holdings in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 9.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 32,139 shares of the company’s stock after selling 3,548 shares during the period. Marquette Asset Management LLC’s holdings in Sera Prognostics were worth $192,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of SERA. Resource Consulting Group Inc. purchased a new stake in Sera Prognostics during the fourth quarter worth approximately $265,000. Vanderbilt University purchased a new position in shares of Sera Prognostics in the fourth quarter valued at $284,000. Perigon Wealth Management LLC purchased a new position in shares of Sera Prognostics in the fourth quarter valued at $509,000. Finally, CWM LLC purchased a new position in shares of Sera Prognostics in the fourth quarter valued at $242,000. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Sera Prognostics Price Performance

Shares of SERA stock traded up $0.41 on Friday, hitting $10.75. The stock had a trading volume of 59,111 shares, compared to its average volume of 138,989. The stock’s 50 day moving average is $9.44 and its 200-day moving average is $6.21. Sera Prognostics, Inc. has a 52-week low of $1.52 and a 52-week high of $11.32.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.10 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 45.74%. Equities research analysts anticipate that Sera Prognostics, Inc. will post -0.94 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Paul Kearney sold 4,984 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $40,021.52. Following the completion of the transaction, the insider now directly owns 160,066 shares in the company, valued at $1,285,329.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, General Counsel Benjamin Jackson sold 5,665 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $45,489.95. Following the sale, the general counsel now directly owns 152,035 shares of the company’s stock, valued at $1,220,841.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul Kearney sold 4,984 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total transaction of $40,021.52. Following the completion of the sale, the insider now directly owns 160,066 shares in the company, valued at $1,285,329.98. The disclosure for this sale can be found here. Over the last three months, insiders sold 141,335 shares of company stock worth $1,255,192. 15.60% of the stock is currently owned by company insiders.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.